Physician profile
Kurt Sowers
NPI 1467550483
$118,517.14
in general payments reported to CMS, 2019-2025
21 companies · $9,341 in 2025
The $9,341 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $8,964 · 2021: $1,785 · 2022: $23K · 2023: $46K · 2024: $17K · 2025: $9,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Consulting Fee: $6,446 · Travel and Lodging: $5,660 · Food and Beverage: $2,887 · Education: $15.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,310.00 |
| Consulting Fee | $6,446.00 |
| Travel and Lodging | $5,659.85 |
| Food and Beverage | $2,886.65 |
| Education | $15.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $63,764.05 | 2022-2025 | Farxiga, Lokelma, Brilinta |
| Mallinckrodt Hospital Products INC. | $21,248.79 | 2020-2023 | Acthar |
| Otsuka America Pharmaceutical, INC. | $13,978.40 | 2019-2024 | Jynarque |
| Mallinckrodt Enterprises LLC | $12,491.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,870.96 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $2,059.14 | 2024 | |
| La Jolla Pharmaceutical Company | $273.42 | 2023-2025 | Xacduro, Xerava |
| Melinta Therapeutics, LLC | $271.60 | 2022-2024 | Rezzayo, Vabomere, Kimyrsa |
| Takeda Pharmaceuticals U.S.A., INC. | $216.77 | 2021-2023 | Entyvio |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.59 | 2023 | Jynarque |
| Lilly USA, LLC | $61.98 | 2021-2023 | Jardiance |
| Novo Nordisk INC | $50.01 | 2025 | Ozempic |
| Opko Pharmaceuticals, LLC | $28.65 | 2019-2025 | Rayaldee |
| Paratek Pharmaceuticals, INC. | $24.19 | 2024 | Nuzyra |
| Abbvie INC. | $21.24 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.53 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.01 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $14.93 | 2020 | |
| Shire North American Group INC | $14.08 | 2019 | |
| Lundbeck LLC | $13.90 | 2019 | |
| Csl Behring | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Sowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.